Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective C  

$1,061,221.55
Fiscal Year: 2009

Yellow dot: Objective has some degree of funding, but less than the recommended amount.4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.

Download 2009 Question 4: Long-term Objective C projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
ADHD symptoms in autism: Cognition, behavior, treatment Pearson, Deborah University of Texas Health Science Center at Houston
Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine Arnold, L. Eugene The Ohio State University
Open label risperidone in children and adolescents with autistic disorder Kolevzon, Alexander Mount Sinai School of Medicine
Pharmacogenomics in autism treatment Hendren, Robert University of California, Davis
Pharmacogenomics in autism treatment Hendren, Robert University of California, Davis
Pharmacotherapy of pervasive developmental disorders Stigler, Kimberly Indiana University-Purdue University Indianapolis
Targeted pharmacologic interventions for autism Posey, David Indiana University-Purdue University Indianapolis

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015.

IACC Recommended Budget: $10,000,000 over 5 years
N/A

4.L.C
$1,061,222
7 projects

4.L.C
$2,302,240
7 projects

4.L.C
$2,834,887
8 projects

4.L.C
$277,072
3 projects

$6,475,421
4.L.C. Funding: The recommended budget was partially met. 

Progress: A small number (3-7) of studies of pharmacological interventions for co-occurring conditions was funded. There exist many studies examining drugs that are in active use for ADHD that are now being adapted to ADHD-ASD patient groups.

Remaining Gaps, Needs, and Opportunities: There currently is much need for greater understanding of drug efficacy in ASD populations.